Involvement of Autophagy in Levodopa‐Induced Dyskinesia
Autor: | Carina Plewnia, Lidia Urbina, David Sulzer, Erwan Bezard, Mikael Altun, Michael Feyder, Benjamin Dehay, Anders Borgkvist, Per Nilsson, Qin Li, Giada Spigolon, Emanuela Santini, Alessandro Piccin, Gilberto Fisone, Ori J. Lieberman |
---|---|
Přispěvatelé: | Karolinska Institutet [Stockholm], Columbia University [New York], New York State Psychiatric Institute, Institut des Maladies Neurodégénératives [Bordeaux] (IMN), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), Motac Neuroscience Ltd [Manchester, UK], China Academy of Medical Sciences [Beijing, China] (Institute of Laboratory Animal Sciences), Karolinska University Hospital [Stockholm], Dehay, Benjamin |
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Levodopa Dyskinesia Drug-Induced autophagy Parkinson's disease striatum [SDV]Life Sciences [q-bio] mTORC1 Striatum Regular Issue Articles l‐dopa Pharmacology Antiparkinson Agents 03 medical and health sciences Mice 0302 clinical medicine Parkinsonian Disorders Dopamine L-dopa Medicine Animals Humans Oxidopamine Research Articles Levodopa-induced dyskinesia business.industry Autophagy p62 medicine.disease Corpus Striatum 3. Good health nervous system diseases [SDV] Life Sciences [q-bio] Disease Models Animal 030104 developmental biology Neurology Dyskinesia Parkinson’s disease Neurology (clinical) medicine.symptom business 030217 neurology & neurosurgery medicine.drug Research Article |
Zdroj: | Movement Disorders Movement Disorders, Wiley, 2021, Online ahead of print. ⟨10.1002/mds.28480⟩ Movement Disorders, 2021, Online ahead of print. ⟨10.1002/mds.28480⟩ |
ISSN: | 0885-3185 1531-8257 |
DOI: | 10.1002/mds.28480⟩ |
Popis: | Background Autophagy is intensively studied in cancer, metabolic and neurodegenerative diseases, but little is known about its role in pathological conditions linked to altered neurotransmission. We examined the involvement of autophagy in levodopa (l‐dopa)‐induced dyskinesia, a frequent motor complication developed in response to standard dopamine replacement therapy in parkinsonian patients. Methods We used mouse and non‐human primate models of Parkinson's disease to examine changes in autophagy associated with chronic l‐dopa administration and to establish a causative link between impaired autophagy and dyskinesia. Results We found that l‐dopa‐induced dyskinesia is associated with accumulation of the autophagy‐specific substrate p62, a marker of autophagy deficiency. Increased p62 was observed in a subset of projection neurons located in the striatum and depended on l‐dopa‐mediated activation of dopamine D1 receptors, and mammalian target of rapamycin. Inhibition of mammalian target of rapamycin complex 1 with rapamycin counteracted the impairment of autophagy produced by l‐dopa, and reduced dyskinesia. The anti‐dyskinetic effect of rapamycin was lost when autophagy was constitutively suppressed in D1 receptor‐expressing striatal neurons, through inactivation of the autophagy‐related gene protein 7. Conclusions These findings indicate that augmented responsiveness at D1 receptors leads to dysregulated autophagy, and results in the emergence of l‐dopa‐induced dyskinesia. They further suggest the enhancement of autophagy as a therapeutic strategy against dyskinesia. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society May Infographic: Involvement of Autophagy in Levodopa‐Induced Dyskinesia |
Databáze: | OpenAIRE |
Externí odkaz: |